ALPHA IVF GROUP BERHAD

202101005100 (1405399-X)

ALPHA IVF GROUP BERHAD
AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 28 FEBRUARY 2026

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE THIRD QUARTER ENDED 28 FEBRUARY 2026

	Note	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
		28.2.2026 RM'000	28.2.2025 RM'000	28.2.2026 RM'000	28.2.2025 RM'000
Revenue	A9	**47,123**	**40,596**	**146,517**	**126,835**
Cost of sales		(19,059)	(16,062)	(58,958)	(50,315)
Gross profit		**28,064**	**24,534**	**87,559**	**76,520**
Other income		1,574	1,561	4,757	4,820
Administrative expenses		(10,150)	(9,558)	(31,311)	(24,121)
Other expenses		(1,971)	(733)	(5,194)	(1,755)
Finance costs		(544)	(223)	(1,387)	(697)
Profit before taxation ("PBT")	B12	**16,973**	**15,581**	**54,424**	**54,767**
Income tax expense	B6	(4,818)	(3,491)	(15,049)	(12,455)
Profit after taxation ("PAT")		**12,155**	**12,090**	**39,375**	**42,312**
Other comprehensive income					
Item that will be reclassified subsequently to profit or loss					
Foreign currency translation differences		(1,898)	(80)	(3,450)	(514)
Total comprehensive income		10,257	12,010	35,925	41,798
Profit after taxation attributable to:					
Owners of the Company		12,457	11,905	39,735	41,386
Non-controlling interests		(302)	185	(360)	926
		12,155	12,090	39,375	42,312
Total comprehensive income attributable to:					
Owners of the Company		10,829	11,827	36,768	40,965
Non-controlling interests		(572)	183	(843)	833
		10,257	12,010	35,925	41,798
Earnings per share attributable to Owners of the Company					
Basic/Diluted (sen)(1)	B11	0.26	0.24	0.82	0.85

Note:
(1) The basic and diluted earnings per share of the Company are computed based on PAT attributable to the Owners of the Company divided by the weighted average number of ordinary shares outstanding during the period, excluding treasury shares of the Company referred to in Note B11. The Group has not issued any dilutive potential ordinary shares and hence, the diluted earnings per share is equal to the basic earnings per share.

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 28 FEBRUARY 2026

	Unaudited	Audited
	As at 28.2.2026 RM'000	**As at 31.5.2025 RM'000**
ASSETS		
Non-Current Assets		
Equipment	27,715	13,767
Right-of-use assets	40,445	22,425
Other investments	30,434	30,563
Goodwill	8,931	8,931
Deferred tax assets	1,700	1,702
	109,225	77,388
Current Assets		
Inventories	3,957	2,817
Trade receivables	1,766	1,590
Other receivables, deposits and prepayments	14,128	13,127
Current tax asset	105	5
Short-term investments	103,805	121,449
Cash and bank balances	39,606	34,432
	163,367	173,420
TOTAL ASSETS	272,592	250,808
EQUITY AND LIABILITIES		
Share capital	119,753	119,753
Treasury shares	(557)	-
Retained profits	44,052	55,971
Reorganisation reserve	22,499	22,499
Foreign exchange translation reserve	(3,152)	(185)
Equity attributable to Owners of the Company	182,595	198,038
Non-controlling interests	6,074	6,109
Total Equity	188,669	204,147
Non-Current Liabilities		
Lease liabilities	31,902	21,659
Provision for restoration costs	1,253	1,227
	33,155	22,886
Current Liabilities		
Trade payables	1,321	2,808
Other payables and accruals	31,973	5,701
Contract liabilities	8,016	8,329
Lease liabilities	2,933	1,848
Current tax liabilities	6,525	5,089
	50,768	23,775
Total Liabilities	83,923	46,661
TOTAL EQUITY AND LIABILITIES	272,592	250,808
Net assets per ordinary share attributable to Owners of the Company (RM)	0.04	0.04

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE THIRD QUARTER ENDED 28 FEBRUARY 2026

	Share Capital	Treasury shares	Reorganisation Reserve	Foreign Exchange Translation Reserve	Retained Profits	Attributable to Owners of the Company	Non-Controlling Interests	Total Equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
As at 1 June 2025	119,753	-	22,499	(185)	55,971	198,038	6,109	204,147
Profit after taxation for the financial period	-	-	-	-	39,735	39,735	(360)	39,375
Other comprehensive expenses for the financial period:								
- Foreign currency translation differences	-	-	-	(2,967)	-	(2,967)	(483)	(3,450)
Total comprehensive (expenses)/income for the financial period	-	-	-	(2,967)	39,735	36,768	(843)	35,925
Repurchase of treasury shares of the Company	-	(557)	-	-	-	(557)	-	(557)
Dividend by the Company	-	-	-	-	(48,600)	(48,600)	-	(48,600)
Acquisition of additional interests in a subsidiary	-	-	-	-	(3,054)	(3,054)	(2,722)	(5,776)
Ordinary share capital contributed by non-controlling interests	-	-	-	-	-	-	3,530	3,530
As at 28 February 2026	119,753	(557)	22,499	(3,152)	44,052	182,595	6,074	188,669

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE THIRD QUARTER ENDED 28 FEBRUARY 2026

	Period Ended 28.2.2026 RM'000	Period Ended 28.2.2025 RM'000
CASH FLOW FROM OPERATING ACTIVITIES		
Profit before taxation	54,424	54,767
Adjustments for:		
Depreciation of equipment	3,689	1,838
Depreciation of right-of-use assets	3,356	2,252
Interest expenses	1,387	697
Equipment written off	62	-
Gain on disposal of equipment	(20)	(60)
Gain on termination of lease	(1)	-
Fair value gain on unit trust funds	(98)	-
Dividend income from a short-term investment	(6)	-
Unrealised loss on foreign exchange	1,067	-
Interest income	(3,389)	(4,302)
Operating profit before working capital changes	60,471	55,192
Changes in working capital:		
Inventories	(1,167)	(374)
Trade and other receivables	(1,510)	(2,556)
Trade and other payables	(408)	(2,981)
Contract liabilities	(273)	645
CASH FROM OPERATIONS	57,113	49,926
Income tax paid	(13,713)	(13,058)
NET CASH FROM OPERATING ACTIVITIES	43,400	36,868
CASH FLOW (FOR)/FROM INVESTING ACTIVITIES		
Acquisition of additional interest in a subsidiary	(5,776)	-
Proceed from disposal of equipment	20	70
Dividend income from a short-term investment	6	-
Interest income	3,089	4,302
Purchase of equipment	(18,442)	(3,548)
Additional right-of-use assets	(453)	-
Withdrawal of short-term investments	17,967	23,347
NET CASH (FOR)/FROM INVESTING ACTIVITIES	(3,589)	24,171
CASH FLOW FOR FINANCING ACTIVITIES		
Dividend paid by the Company	(24,300)	(46,170)
Repurchase of own shares	(557)	-
Proceeds from issuance of share capital to non-controlling interests	3,530	1,967
Interest paid	(1,232)	(523)
Repayment of lease liabilities	(10,071)	(2,354)
NET CASH FOR FINANCING ACTIVITIES	(32,630)	(47,080)
Net increase in cash and cash equivalents	7,181	13,959
Effect of foreign exchange translation	(1,351)	(278)
Cash and cash equivalents at beginning of the financial period	59,584	22,906
Cash and cash equivalents at end of the financial period	65,414	36,587

Note:

Cash and cash equivalents comprise of the following:

Short-term investments - money market funds	25,808	-
Cash and bank balances	39,606	36,587
	65,414	36,587

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 28 FEBRUARY 2026

A1. Basis of Preparation

The interim financial report of Alpha IVF Group Berhad ("Company") and its subsidiaries ("Group") are unaudited and have been prepared in accordance with requirements of Malaysian Financial Reporting Standards ("MFRS") No. 134: Interim Financial Reporting and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 as disclosed in the Annual Report 2025 and the accompanying notes attached to this interim financial report.

A2. Summary of Significant Accounting Policies

The significant accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted in the most recent audited annual financial statements for the year ended 31 May 2025. During the current financial period, the Group has adopted the following new accounting standards and/or interpretations (including the consequential amendments, if any):

MFRSs and/or IC Interpretations (Including the Consequential Amendments)	Effective Date
Amendments to MFRS 121: Lack of Exchangeability	1 January 2025

The adoption of the above accounting standards and/or interpretations (including the consequential amendments, if any) did not have any material impact on the Group's financial statements.

The Group has not applied in advance the following accounting standards and/or interpretations (including the consequential amendments, if any) that have been issued by the Malaysian Accounting Standard Board ("MASB") but are not yet effective for the financial period ended 28 February 2026:

MFRSs and/or IC Interpretations (Including the Consequential Amendments)	Effective Date
Annual Improvements to MFRS Accounting Standards – Volume 11	1 January 2026
Amendments to MFRS 9 and MFRS 7: Amendments to the Classification and Measurement of Financial Instruments	1 January 2026
Amendments to MFRS 9 and MFRS 7: Contracts Referencing Nature-dependent Electricity	1 January 2026
MFRS 18: Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19: Subsidiaries without Public Accountability: Disclosures	1 January 2027
MFRS 121: Translation to a Hyperinflationary Presentation Currency	1 January 2027
Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred

The Group is in process of assessing the impact of implementing the above accounting standards and/or interpretations in the year of initial application.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 28 FEBRUARY 2026 (CONT'D)

A3. Auditors' Report on preceding Annual Financial Statements

There was no qualification on the audited consolidated financial statements of the Group for the financial year ended 31 May 2025.

A4. Seasonal or cyclical factors

The business operation of the Group has not been materially affected by any unusual seasonal or cyclical factors.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and financial period-to-date.

A6. Material changes in estimates

There were no material changes in estimates that have a material effect to the Group in the current financial quarter and financial period-to-date.

A7. Debt and equity securities

As at 28 February 2026, the Company had repurchased and held a cumulative total of 2,097,300 of its issued ordinary shares as treasury shares in accordance with Section 127 of the Companies Act 2016. After deducting these treasury shares, the number of ordinary shares in circulation stood at 4,857,902,700.

Other than the above, there were no issuance, cancellation, repurchase, resale and repayment of debt and equity securities during the current financial quarter under review.

A8. Dividends Paid

The Company had declared a second single-tier interim dividend of 0.50 sen per ordinary share amounting to RM24,300,000, on 28 July 2025, in respect of the financial year ended 31 May 2025. The dividend was paid on 29 August 2025 and the entitlement date was on 11 August 2025.

The Company had declared a first single-tier interim dividend of 0.50 sen per ordinary share amounting to RM24,214,655.91, on 22 January 2026, in respect of the financial year ending 31 May 2026. The dividend was paid on 31 March 2026 and the entitlement date was on 19 March 2026.

The total dividend of RM48,514,655.91 declared and paid has been accounted for in equity as an appropriation of retained earnings for the financial year ending 31 May 2026.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 28 FEBRUARY 2026 (CONT'D)

A9. Segmental Reporting

The Group operates predominantly in one business segment i.e. focused only in the business of operating women's specialists centres and provision of medical consultants and specialised medical services. Accordingly, the information by business segments is not presented.

Geographical Market

The following table provides an analysis of the Group's revenue by geographical segment:

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	28.2.2026	28.2.2025	28.2.2026	28.2.2025
	RM'000	RM'000	RM'000	RM'000
Revenue				
- Malaysia	42,467	37,330	133,403	110,710
- Singapore	3,745	3,266	11,512	16,125
- Indonesia	471	-	1,162	-
- Philippines	440	-	440	-
	47,123	40,596	146,517	126,835

A10. Valuation of Equipment

There was no valuation of equipment in the current financial quarter under review.

A11. Material events subsequent to the end of the current financial quarter

There are no material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

A12. Changes in the composition of the Group

Save as disclosed below, there were no changes in the composition of the Group during the current financial quarter under review.

(a) Increase of issued and paid-up capital of Alpha IVF System Sdn. Bhd. ("AIS")

On 13 January 2026, AIS, a wholly-owned subsidiary of the Company, increased its issued and paid-up capital from RM31,200,000 to RM35,200,000 by the issuance of 4,000,000 new ordinary shares. The Company subscribed for the additional 4,000,000 ordinary shares at RM1 each.

(b) Increase of issued and paid-up capital of Alpha IVF (Tuguegarao) Incorporation ("AITI")

On 28 January 2026, AITI, an indirect subsidiary of the Company, increased its issued and paid-up capital from RM931,855 to RM9,815,146 by issuance of an aggregate of 125,000,000 new ordinary shares at Philippine peso ("PHP") 1 (approximately RM0.07). AIS, a wholly-owned subsidiary of the Company, have subscribed 111,250,000 new ordinary shares at RM0.07 per share.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 28 FEBRUARY 2026 (CONT'D)

A12. Changes in the composition of the Group (Cont'd)

(c) Increase of issued and paid-up capital of Alpha International Women's Specialists (Johor) Sdn. Bhd. ("AIWSJ")

On 26 January 2026, AIWSJ a wholly-owned subsidiary of the Company, increased its issued and paid-up capital from RM701,000 to RM901,000 by issuance of 200,000 new ordinary shares. The Company subscribed for the additional 200,000 ordinary shares at RM1 each.

A13. Contingent Assets and Contingent Liabilities

There were no contingent assets and contingent liabilities as at the date of this interim financial report.

A14. Material capital commitments

Save as disclosed below, there is no material commitment for capital expenditure, which upon becoming enforceable, may have a material effect on the Group's financial position as at the date of this interim financial report.

	28.2.2026	28.2.2025
	RM'000	RM'000
Purchase of equipment	19,111	6,788

(THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK)

ALPHA IVF GROUP BERHAD
Registration No. 202101005100 (1405399-X)
(Incorporated in Malaysia)

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 28 FEBRUARY 2026 (CONT'D)

A15. Significant related party transactions

The Group carried out the following significant transactions with related parties during the financial period:

Transacting Parties	Nature of transaction	CURRENT QUARTER ENDED 28.02.2026 RM'000	CURRENT QUARTER ENDED 28.02.2025 RM'000	CUMMULATIVE PERIOR ENDED 28.02.2026 RM'000	CUMMULATIVE PERIOR ENDED 28.02.2025 RM'000
Significant transactions with Directors of the Company					
(i) AIWS and Dato' Dr. Lee Soon Soo ("DDLSS")	Consultancy services provided by DDLSS	(316)	(279)	(1,001)	(926)
(ii) Genesis and Dr. Ng Peng Wah ("DNPW")	Consultancy services provided by DNPW	(643)	(637)	(2,116)	(2,061)
Significant transactions with Directors of the Subsidiaries					
(iii) AIWS and Dr. Haris Bin Hamzah ("Dr. Haris")	Consultancy services provided by Dr. Haris	(43)	(66)	(165)	(157)
(iv) Alhaya and Dr. Haris	Consultancy services provided by Dr. Haris	(47)	(61)	(121)	(185)
Significant transactions with Related Parties					
(v) AIWSS and Dr. Tan Heng Hao ("Dr. Tan")	Consultancy services provided by Dr. Tan	#	(35)	(54)	(3,054)
(vi) AIWSS and Dr. Tan	Administrative fee income charged to Dr. Tan	-	-	-	43
(vii) AIWS and Baby Xort Sdn. Bhd. ("Baby Xort")	Sperm sorting services provided by Baby Xort	(57)	(150)	(354)	(452)
(viii) Alhaya and Baby Xort	Sperm sorting services provided by Baby Xort	-	(7)	(7)	(7)

AIWS – Alpha International Women's Specialists Sdn. Bhd.
AIWSS – Alpha International Women's Specialists (Singapore) Pte. Ltd.
Genesis – Genesis Specialists Sdn. Bhd.
Alhaya – Alhaya International Women's Specialists Sdn. Bhd.

\# – Less than RM1,000.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

B1. Review of Performance

(a) Results for current quarter

For the financial quarter ended 28 February 2026, the Group recorded a revenue of RM47.12 million, representing an increase of RM6.52 million or 16.06% as compared to RM40.60 million in the preceding year corresponding quarter ended 28 February 2025. The revenue increased is due to higher sales especially from local and China patients in the Malaysian centres. The Group's revenue was principally derived from the provision of assisted reproductive services focusing on in-vitro fertilisation ("IVF") treatments.

The Group recorded a PBT of RM16.97 million and PAT of RM12.16 million for the current financial quarter as compared to a PBT of RM15.58 million and PAT of RM12.09 million for the preceding year corresponding quarter ended 28 February 2025. The increase in PBT by RM1.39 million or 8.92% and PAT by RM0.07 million or 0.58% was primarily due to higher sales from the provision of assisted reproductive services.

(b) Results for financial period-to-date

For the financial period ended 28 February 2026, the Group recorded a revenue of RM146.52 million, representing an increase of RM19.68 million or 15.52% as compared to RM126.84 million in the preceding corresponding period ended 28 February 2025. The increase was primarily attributable to higher sales from local and foreign patients in the Malaysian centres. The Group's revenue continued to be principally derived from the provision of assisted reproductive services focusing on IVF treatments.

The Group recorded a PBT of RM54.42 million and PAT of RM39.38 million for the current financial period, representing a decrease of RM0.35 million or 0.64% in PBT and RM2.93 million or 6.93% in PAT as compared to the preceding corresponding period ended 28 February 2025. The lower PBT and PAT were primarily due to increased pre-operational costs related to the Group's ongoing expansion initiatives.

B2. Comparison with immediate preceding quarter's results

On a quarter-on-quarter basis, the Group recorded revenue of RM47.12 million, representing a decrease of RM0.18 million or 0.38% compared to RM47.30 million in the immediate preceding quarter ended 30 November 2025. The decline in revenue was mainly attributable to lower sales from Malaysian centres during the current quarter under review.

The Group recorded a PBT of RM16.97 million and PAT of RM12.16 million in the current financial quarter ended 28 February 2026, representing an increase of RM0.50 million or 3.04% in PBT and RM0.31 million or 2.62% in PAT compared to the immediate preceding quarter ended 30 November 2025, which recorded a PBT of RM16.47 million and PAT of RM11.85 million. The increase in PBT and PAT were primarily due to the lower pre-operating costs related to expansion initiatives.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B3. Prospects

Demand for Assisted Reproductive Services ("ARS") remains resilient and is not directly affected by geopolitical conflicts. The ongoing trend of delayed parenthood, coupled with declining fertility rates, continues to support demand for ARS. Against this backdrop, the Group remains focused on executing its expansion strategy across both domestic and regional markets.

Newly established full-fledged IVF centres in Sabah and Manila have shown an encouraging start and are expected to contribute more meaningfully going forward.

Beyond these, the Group is also developing two additional full-fledged IVF centres, one in Johor, Malaysia, and another overseas centre in Tuguegarao, Philippines, which are expected to be operational by 1H FY27.

In addition, the Group is actively advancing its expansion in Indonesia, a key growth market, with the development of full-fledged IVF centres in Jakarta and Bali, the former is targeted to commence operations by 1H FY27 and the latter by end 2027, reinforcing its long-term growth strategy and regional footprint.

With the progressive rollout of these new centres, the Group is expected to achieve a stronger growth trajectory, further strengthening its position as a leading regional fertility treatment specialist.

While near-term earnings may be impacted by upfront costs associated with new centre openings and ongoing expansion initiatives, the Group expects performance to gradually improve as these centres mature, and utilisation rates increase. Backed by its established brand, clinical expertise, and growing network, the Group remains well-positioned to deliver sustainable growth and create long-term value for its stakeholders.

B4. Profit forecast or profit guarantee

The Group did not issue any profit forecast or profit guarantee in any public document in respect of the interim financial reporting period under review.

B5. Status of corporate proposals

There were no corporate proposals announced but not completed as at the date of this interim financial report.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B6. Income tax expense

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	28.2.2026	28.2.2025	28.2.2026	28.2.2025
	RM'000	RM'000	RM'000	RM'000
Income tax expense				
- Current year	4,807	3,874	15,038	12,840
- Prior year	11	(383)	11	(383)
Deferred tax expense				
- Current year	-	#	-	(2)
- Prior year	-	-	-	-
	4,818	3,491	15,049	12,455
Effective tax rate (%)	28%	22%	28%	23%

The Group's effective tax rate for the current quarter and financial period ended 28 February 2026 was higher than the statutory tax rate of 24%, mainly because of deferred tax assets were not recognised on temporary differences arising from unused tax losses in certain subsidiaries.

- Less than RM1,000.

(THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK)

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B7. Utilisation of Proceeds from the Initial Public Offering ("IPO")

The gross proceeds raised from the Public Issue is RM116.64 million and the status of the utilisation of proceeds as at 28 February 2026 is as follows:

Details of utilisation	Initial	After variations [(1)]	Utilised as at 28 February 2026	Unutilised IPO Proceeds	Timeframe for utilisation
	RM'000	RM'000	RM'000	RM'000	
Establishing new medical centres, satellite clinics and sales representative offices as follows:-					
(a) Two (2) specialist centres in Malaysia	32,000	21,400	(11,602)	9,798	
(b) Two (2) specialist centres in Indonesia	17,100	17,100	(1,604)	15,496	
(c) Four (4) satellite clinics in Indonesia	7,000	6,200	(4,473)	1,727	
(d) One (1) specialist centre in Laos / Cambodia	13,900	-	-	-	
(e) Two (2) sales representative offices in China	2,800	2,400	(1,739)	661	Within 36 months from the listing date
Expansion and upgrade of existing medical centres, facilities and corporate office	15,700	13,670	(6,590)	7,080	Within 36 months from the listing date
Establishment / acquisition of medical centres, satellite clinics and sales representative offices in Asia including, but not limited to, Malaysia, Indonesia, Philippines and China	-	27,500	(15,441)	12,059	Within 36 months from 21 August 2024
Research and development	2,200	2,200	(1,195)	1,005	Within 36 months from the listing date
General working capital	17,140	17,370	(8,108)	9,262	Within 36 months from the listing date
General corporate purposes	2,600	2,600	(1,596)	1,004	Within 36 months from the listing date
Defraying the listing expenses	6,200	6,200	(6,200) [(2)]	-	Within 1 month from the listing date
Total	116,640	116,640	(58,548)	58,092	

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B7. Utilisation of Proceeds from the IPO (Cont'd)

The utilisation of proceeds as disclosed above should be read in conjunction with the Prospectus dated 1 March 2024 in relation to its IPO and the announcement on variations of utilisation of IPO proceeds dated 21 August 2024.

Notes:

(1) The Company had varied the utilisation of IPO Proceeds to reallocate a total of RM27.73 million or approximately 23.77% for (i) establishing new medical centres, satellite clinics and sales representative offices and (ii) expansion and upgrade of existing medical centres, facilities and corporate office to (i) establishment / acquisition of medical centres, satellite clinics and sales representative offices in Asia including, but not limited to, Malaysia, Indonesia, Philippines and China as well as (ii) general working capital.

(2) The listing expenses of RM5.89 million have been fully paid and the balance of RM0.31 million will be used as working capital of the Group. The Company has since fully utilised the RM0.31 million for working capital purpose.

B8. Group Borrowings and Debt Securities

There were no group borrowings and debt securities as at 28 February 2026 and 31 May 2025.

B9. Material Litigation

There was no material litigation involving the Group as at 28 February 2026.

B10. Dividend Proposed or Declared

Save as disclosed in item A8, there were no other dividends proposed and declared as at the date of this report.

B11. Earnings per share

The basic earnings per share ("EPS") is calculated by dividing the profit for the period attributable to Owners of the Company by weighted average number of ordinary shares (excluding treasury shares) of the Company during the financial period as follows:

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	28.2.2026	28.2.2025	28.2.2026	28.2.2025
Profit attributable to Owners of the Company (RM'000)	12,457	11,905	39,735	41,386
Weighted average number of ordinary shares (excluding treasury shares) ('000)	4,859,930	4,860,000	4,859,977	4,860,000
Basic/Diluted EPS (sen)	0.26	0.24	0.82	0.85

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B12. Notes to the Condensed Statement of Profit or Loss and Other Comprehensive Income

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	28.2.2026	28.2.2025	28.2.2026	28.2.2025
	RM'000	RM'000	RM'000	RM'000
Profit before taxation is arrived at after charging/(crediting):				
Depreciation of equipment	1,525	622	3,689	1,838
Depreciation of right-of-use assets	1,198	884	3,356	2,252
Fair value gain on short-term investments:				
- money market funds	(202)	-	(618)	-
- unit trust funds	(25)	-	(98)	-
Dividend income from a short-term investment	(2)	-	(6)	-
Interest income	(1,063)	(1,353)	(3,389)	(4,302)
Interest expenses	544	223	1,387	697
Equipment written off	2	-	62	-
Gain on disposal of equipment	-	(61)	(20)	(60)
Gain on termination of lease	-	-	(1)	-
Unrealised loss in foreign exchange	270	-	1,067	-
Realised gain in foreign exchange	(142)	(39)	(221)	(37)

B13. Approval of Interim Financial Report

The interim financial report as set out above was authorised for issuance by the Board of Directors on 28 April 2026.